Literature DB >> 15539646

Highly active antiretroviral therapy.

Peter Mugyenyi.   

Abstract

Mesh：

Year:  2004        PMID： 15539646      PMCID： PMC527674          DOI： 10.1136/bmj.329.7475.1118

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Community-based approaches to HIV treatment in resource-poor settings.

Authors:  P Farmer; F Léandre; J S Mukherjee; M Claude; P Nevil; M C Smith-Fawzi; S P Koenig; A Castro; M C Becerra; J Sachs; A Attaran; J Y Kim
Journal:  Lancet       Date:  2001-08-04       Impact factor: 79.321

2.  High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

Authors:  C Adjé; R Cheingsong; T H Roels; C Maurice; G Djomand; W Verbiest; K Hertogs; B Larder; B Monga; M Peeters; S Eholie; E Bissagene; M Coulibaly; R Respess; S Z Wiktor; T Chorba; J N Nkengasong
Journal:  J Acquir Immune Defic Syndr       Date:  2001-04-15       Impact factor: 3.731

3.  The burden of HIV / AIDS on the Zambian health system.

Authors:  M Mpundu
Journal:  AIDS Anal Afr       Date:  2000 Feb-Mar

Review 4.  HAART for hospital health care workers--an innovative programme.

Authors:  Kerry Uebel; Gerald Friedland; Robert Pawinski; Helga Holst
Journal:  S Afr Med J       Date:  2004-06

Review 5.  Expanding antiretroviral therapy in Malawi: drawing on the country's experience with tuberculosis.

Authors:  Anthony D Harries; Edwin Libamba; Erik J Schouten; Andrina Mwansambo; Felix M Salaniponi; Rex Mpazanje
Journal:  BMJ       Date:  2004-11-13

6.  Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting.

Authors:  Jessica H Oyugi; Jayne Byakika-Tusiime; Edwin D Charlebois; Cissy Kityo; Roy Mugerwa; Peter Mugyenyi; David R Bangsberg
Journal:  J Acquir Immune Defic Syndr       Date:  2004-08-15       Impact factor: 3.731
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.